KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) Debt to Equity (2016 - 2025)

Charles River Laboratories International has reported Debt to Equity over the past 17 years, most recently at $0.67 for Q4 2025.

  • For Q4 2025, Debt to Equity rose 4.14% year-over-year to $0.67; the TTM value through Dec 2025 reached $0.67, up 4.14%, while the annual FY2025 figure was $0.67, 4.14% up from the prior year.
  • Debt to Equity for Q4 2025 was $0.67 at Charles River Laboratories International, up from $0.64 in the prior quarter.
  • Over five years, Debt to Equity peaked at $1.19 in Q3 2021 and troughed at $0.61 in Q3 2024.
  • A 5-year average of $0.86 and a median of $0.8 in 2025 define the central range for Debt to Equity.
  • Biggest five-year swings in Debt to Equity: rose 12.36% in 2021 and later plummeted 31.98% in 2023.
  • Year by year, Debt to Equity stood at $1.05 in 2021, then dropped by 13.51% to $0.91 in 2022, then dropped by 19.09% to $0.73 in 2023, then fell by 11.93% to $0.65 in 2024, then rose by 4.14% to $0.67 in 2025.
  • Business Quant data shows Debt to Equity for CRL at $0.67 in Q4 2025, $0.64 in Q3 2025, and $0.69 in Q2 2025.